Skip to main content
All Posts By


Vallon Pharmaceuticals Announces Issuance of U.S. Patent Covering ADAIR for the Treatment of Cognitive Impairment Associated with COVID-19

By Press Release

– Company in ongoing discussions with a major academic research center for design and execution of proof-of-concept study evaluating ADAIR for the treatment of cognitive impairment associated with COVID-19 PHILADELPHIA, PA, Feb. 28, 2022 (GLOBE NEWSWIRE) — Vallon Pharmaceuticals, Inc. (NASDAQ:…

Read More